- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Fresenius pulls one batch of Actemra biosim over glass particle concerns | ||
| Mi | Snapchat creates ad format to support pharma disclosure needs | ||
| 11.08. | WuXi AppTec scores temporary win amid fight over DOD's Chinese military company brand | ||
| 11.08. | Attruby cruises toward blockbuster land as BridgeBio CEO spots 'stabilizer-first' ATTR market | ||
| 10.08. | Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path | ||
| 10.08. | Abbott casts telenovela star Gabriela Spanic to take the drama out of colon cancer screening | ||
| 10.08. | ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms | ||
| 10.08. | Bristol Myers Squibb lays out plan for $2.3B manufacturing facility in Houston | ||
| 10.08. | Scholar Rock ditches Novo's legacy Catalent plant in FDA refiling of SMA drug | ||
| 10.08. | Quanterix hires GE Healthcare, Exact Sciences alum as chief commercial officer | ||
| 07.08. | Lilly's Zepbound remains physicians' favorite, even as oral obesity launches altar landscape | ||
| 07.08. | AbbVie's Skyrizi retakes edge in pharma's July ad spending league | ||
| 07.08. | Novo Nordisk makes Omnicom agency of record for US media buying | ||
| 07.08. | Fresenius Kabi recalls mislabeled morphine lot that could cause overdose death | ||
| 06.08. | Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle | ||
| 06.08. | Sarepta's new CEO Michael Severino faces critical milestones to prove growth | ||
| 06.08. | Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful | ||
| 06.08. | Sanofi asked to change Dupixent ads after Galderma challenge | ||
| 05.08. | AstraZeneca, CSPC to form joint venture for biologics manufacturing | ||
| 05.08. | Alcon survey spots gaps in teen eye care ahead of back-to-school season | ||
| 05.08. | Lilly's obesity pill Foundayo 'disappointed' in Q2, as injectables continue to boom | ||
| 05.08. | Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow | ||
| 05.08. | Gilead's HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability | ||
| 05.08. | 'No discussions' ongoing for AstraZeneca-Bristol Myers merger: Reuters | ||
| 04.08. | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.